Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nasal fentanyl vs oral transmucosal fentanyl (Actiq) for breakthrough cancer pain
2006-002087-26Phase 3Completed
- Sponsor
- Takeda
- Start
- Nov 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fentanyl in breakthrough pain and cancer pain (2 arms), sponsored by Takeda. Primary endpoint: Time to onset of meaningful pain relief. Started Nov 2006; status: completed.
02
Drugs
fentanyl
03
Conditions
breakthrough paincancer pain
Beyond the preview
Go deeper on 2006-002087-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002087-26.